Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

Incog BioPharma, a sterile injectables CDMO, plans to shell out around $200 million to boost production capacity at its ...